Galvumet: Mechanism of Action and Uses

Mechanism of Action of Galvumet

Galvumet combines vildagliptin, a DPP-4 inhibitor, and metformin hydrochloride, a biguanide class member, to improve glycaemic control in type 2 diabetes patients.​ Vildagliptin stimulates insulin production by inhibiting DPP-4, while metformin primarily reduces glucose production and acts via AMPK-dependent mechanisms.​

Vildagliptin’s Mechanism of Action

Vildagliptin, a key component of Galvumet, acts by inhibiting DPP-4٫ which leads to increased levels of intact GLP-1 and GIP hormones.​ This increase enhances insulin secretion and reduces glucagon levels in a glucose-dependent manner٫ aiding in better glycaemic control for individuals with type 2 diabetes mellitus.​

Metformin’s Mechanism of Action

Metformin, a component of Galvumet, primarily works by decreasing endogenous hepatic glucose production. It acts via AMP-activated protein kinase (AMPK)-dependent mechanisms and also through other pathways like inhibition of mitochondrial respiration and glycerophosphate dehydrogenase.​ This dual mechanism helps in reducing blood glucose levels effectively in patients with type 2 diabetes mellitus.​

Uses of Galvumet

Galvumet is primarily used in managing type 2 diabetes mellitus by improving glycaemic control.​ It combines vildagliptin and metformin hydrochloride, two agents with different mechanisms of action, to help regulate blood glucose levels effectively in diabetic patients.

Management of Type 2 Diabetes Mellitus

Galvumet, containing vildagliptin and metformin, is particularly effective in managing type 2 diabetes mellitus by improving glycaemic control.​ Vildagliptin’s mechanism involves enhancing insulin secretion and reducing glucagon levels٫ while metformin primarily targets hepatic glucose production.​ The combination of these agents offers a comprehensive approach to regulating blood glucose levels in individuals with type 2 diabetes.

Improvement of Glycaemic Control

To improve glycaemic control in patients with type 2 diabetes mellitus, Galvumet combines vildagliptin and metformin hydrochloride.​ Vildagliptin enhances insulin secretion and suppresses glucagon in a glucose-dependent manner by inhibiting DPP-4, while metformin primarily reduces hepatic glucose production through various mechanisms.​ This dual approach helps regulate blood glucose levels effectively, supporting better management of diabetes.​